ABSTRACT
The world has faced multiple waves of COVID-19 outbreaks, with more than 300 million cases and 5.5 million deaths officially reported globally as of Jan 8, 2022. Within the first year of the pandemic, there was hope that it would soon be under control, yet the pandemic sustains to be the world's priority health agenda. This brief communication provides emerging time-sensitive perspectives on the need for a tailored COVID-19 vaccination strategy in Ethiopia by reviewing studies and expert opinions. As of Jan 8, 2022, Ethiopia has reported 443,339 cases and 7,020 COVID-19-related deaths. Only 9,361,640 people (8%) of the Ethiopian population received at least one dose of the COVID-19 vaccine. While the short supply of vaccines is mentioned as a major bottleneck, the role of vaccine skepticism is largely overlooked, though the vaccine is the primary means to combat the emergence of new variants. Therefore, we recommend vaccine advocacy and awareness creation, planning for vaccine mandate for certain groups of the society, and targeted vaccination and economical use of the vaccines.
Subject(s)
Vaccination Coverage , COVID-19 Vaccines , COVID-19 Testing , COVID-19 , SARS-CoV-2ABSTRACT
El objetivo de este artículo es proporcionar una guía que sirva para la interpretación y seguimiento de los esfuerzos que se están desarrollando en todo el mundo con el objetivo de obtener una vacuna que pueda generar inmunidad contra el nuevo coronavirus SARS-CoV-2 de 2019, el agente causante de la enfermedad por coronavirus denominada COVID-19. Cinco meses después de haber sido detectada la enfermedad, ya hay 102 vacunas en distintos estadios de desarrollo, registradas por la Organización Mundial de la Salud (OMS), correspondientes a 8 plataformas vacunales con diferentes estrategias, y todos los días aparecen nuevas. Esto representará un enorme desafío de organismos internacionales, para la evaluación, comparación y selección de aquellas que cumplan con los criterios regulatorios indispensables de seguridad y eficacia y que, por otro lado, puedan ser producidas en cantidades suficientes para abastecer la demanda mundial. (AU)
The objective of this article is to provide a guide to help the interpretation and monitoring the efforts that are being carried out worldwide to obtain a vaccine that will be able to generate immunity against the new 2019 SARS-CoV-2 coronavirus, the viral agent causes the disease named COVID-19. Five months after the disease was detected, there are already 102 vaccines at different stages of development, registered by World Health Organization (WHO), corresponding to 8 vaccination platforms base on different strategies, and every day new ones appear. This will represent a huge challenge for international organizations, to evaluate, compare and selects those that will meet the essential regulatory criteria of safety and efficacy and that, would be able to be produced in enough quantities to supply the worldwide demand. Key words: SARS-Cov-2 vaccine, vaccine platform, COVID-19 strategy, attenuated virus, viral vector, viral proteins, viral DNA, viral RNA, nucleic acids, viral like particles, WHO. (AU)